We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Sampling Compared for Leishmaniasis Rapid Test

By LabMedica International staff writers
Posted on 11 Jul 2013
Antibody-detecting rapid diagnostic tests (RDTs) are available to aid in the diagnosis of visceral leishmaniasis (VL), the second most fatal parasitic disease after malaria. More...


Although these RDTs have been developed, validated, and approved for use with serum, they are universally performed using whole blood and therefore it was deemed necessary to determine whether an established RDT is as sensitive on whole blood as on serum.

Tropical medicine specialists at McGill University (Montreal, QC, Canada) working with colleagues at the Rajendra Memorial Research Institute of Medical Sciences (Patna, India) compared serum and blood samples from 624 individuals with symptoms of VL attending the outpatient clinic. They used the rK39 immunochromatographic RDT to assess and evaluate the blood and serum samples from each patient. The test was considered positive when both the control line and the test line appeared red in color.

The rK39 Kalazar Detect RTD (InBios International; USA; Seattle, WA, USA) detected 251 cases who were seropositive on both blood and serum sample. In comparison, 334 were negative on both serum and blood. Notably, there were 26 cases that were negative on blood and positive on serum. These 26 individuals in general had low titer antibodies against rK39 as determined by an enzyme linked immunosorbent assay (ELISA) and follow-up on most of these individuals revealed none had persistent VL symptoms. There were 13 cases that were positive on blood and negative on serum and these were considered to be false positives.

The authors concluded that the major observation from their study was that the concordance of the rK39 RDT performed on serum versus blood was excellent. The test can however be negative on blood and positive on serum when the titer of anti-K39 antibodies is low. We therefore recommend that when an individual from an endemic area has clinical symptoms of VL and the blood rK39 RDT is negative, that the test should be redone two to three weeks later if the symptoms persist since during this interval the titer may increase if the disease begins to progress. The study was published on May 23, 2013, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:
McGill University
Rajendra Memorial Research Institute of Medical Sciences
InBios International


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clinical Chemistry System
P780
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Clinical Chemistry

view channel
Image: The steps involved in the electric field-induced capture and release (EFIRM) assay (Photo courtesy of UCLA School of Dentistry)

Saliva-Based Cancer Detection Technology Eliminates Need for Complex Sample Preparation

Early detection of cancer and other serious diseases is crucial for effective treatment and improved outcomes, yet current diagnostic methods often involve invasive procedures and complex sample preparation.... Read more

Molecular Diagnostics

view channel
Image: The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is FDA-cleared for use in diagnosing Alzheimer’s (Photo courtesy of Fujirebio)

First FDA Cleared Blood Test for Alzheimer’s Diagnosis Marks Turning Point in Early Detection

Alzheimer’s disease is a progressive form of dementia that affects memory, cognition, and behavior, eventually interfering with daily activities. Early and accurate diagnosis is essential to improving... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.